The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach

Vaccine

Volumn 25, Issue 39-40, 2007, Pages 6922-6929

  Bos, J M ^a   Rietveld, E ^b   Moll, H A ^b   Steyerberg, E W ^b   Luytjes, W ^c   Wilschut, J C ^d   de Groot, R ^b,e   Postma, M J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Health economics; RSV; Vaccination

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ARTICLE; CALCULATION; CHILD HOSPITALIZATION; COHORT ANALYSIS; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; NETHERLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TIME SERIES ANALYSIS; VACCINATION; VIRUS INFECTION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG DESIGN; ECONOMICS, MEDICAL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; NETHERLANDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINATION;

EID: 34548548520     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.006     Document Type: Article

References (27)

1. Hoffman S.J., Laham F.R., and Polack F.P. Mechanisms of illness during respiratory syncytial virus infection: the lungs, the virus and the immune response. Microbes Infect 6 8 (2004) 767-772
2. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., and Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282 15 (1999) 1440-1446
3. Henderson F.W., Collier A.M., Sanyal M.A., Watkins J.M., Fairclough D.L., Clyde W.A., et al. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med 306 23 (1982) 1377-1383
4. American Academy of Pediatrics; Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112 (2003) 1442-1446
5. Bont L., Steijn M., van Aalderen W.M., and Kimpen J.L. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J 23 5 (2004) 414-417
6. Paramore L.C., Ciuryla V., Ciesla G., and Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22 5 (2004) 275-284
7. Klein J.O. The burden of otitis media. Vaccine 19 Suppl. 1 (2000) S2-S8
8. Henderson J., Hilliard T.N., Sherriff A., Stalker D., Shammari N.A., Thomas H.M., et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort. Pediatr Allergy Immunol 16 (2005) 386-392
9. Zambon M.C., Stockton J.D., Clewley J.P., and Fleming D.M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 358 9291 (2001) 1410-1416
10. van den Hoogen B.G., de Jong J., Groen J., Kuiken T., de Groot R., Fouchier R.A.M., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7 (2001) 719-724
11. Van den Hoogen B.G., Osterhaus A.D.M.E., and Fouchier R.A.M. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr Infect Dis J 23 (2004) S25-S32
12. Dudas R.A., and Karron R.A. Respiratory syncytial virus vaccines. Clin Microbiol Rev 11 (1998) 430-439
13. Durbin A.P., and Karron R.A. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis 37 12 (2003) 1668-1677
14. Polack F.P., and Karron R.A. The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 23 Suppl. 1 (2004) S65-S73
15. Bos J.M., Alphen Lv., and Postma M.J. The use of modeling in the economic evaluation of vaccines. Expert Rev Pharmacoeconomics Outcomes Res 2 5 (2002) 443-455
16. Rietveld E., de Jonge H.C.C., Polder J.J., Vergouwe Y., Veeze H.J., Moll H.A., et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J 23 6 (2004) 523-529
17. Rietveld E., Vergouwe Y., Steyerberg E.W., Huysman M.W.A., de Groot R., and Moll H.A. Respiratory syncytial virus hospitalisation in young children: development of a clinical prediction rule. Pediatr Infect Dis 25 (2006) 201-207
18. College voor Zorgverzekeringen (CvZ). Guideline prices for pharmacoeconomic research (2004), CvZ, Diemen
19. Miedema C.J., Kors A.W., Tjon a Ten W.E., and Kimpen J.L.L. Medical consumption and socioeconomic effects of infection with respiratory syncytial vius in the Netherlands. Pediatr Infect Dis J 20 2 (2001) 160-163
20. Bos J.M., Rumke H., Welte R., and Postma M.J. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 25 (2003) 2614-2630
21. Altman D.G. Practical statistics for medical research (1991), Chapman and Hall, London
22. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
23. Fleming D.M., Pannell R.S., and Cross K.W. Mortality in children form influenza and respiratory syncytial virus. J Epidemiol Community Health 59 (2005) 586-590
24. Fleming D.M., Pannell R.S., Elliot A.J., and Cross K.W. Respiratory illness associated with influenza and respiratory syncytial virus. Arch Dis Child 90 (2005) 741-746
25. Klok R.M., Brouwer W.B.F., Annemans L.A., Bos J.M., and Postma M.J. Towards a healthier discount procedure. Expert Rev Pharmacoeconomics Outcomes Res 5 (2005) 59-63
26. Bos J.M., and Postma M.J. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?. Expert Rev Pharmacoeconomics Outcomes Res 4 (2004) 247-250
27. Raad voor de Volksgezondheid en Zorg (RVZ). Zicht op Zinnige en Duurzame Zorg (2006), RVZ (Netherlands), The Hague